538965.BO Stock Analysis
53
Avoid
Based on Eyestock quantitative analysis, 538965.BO`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Concord Drugs Ltd. engages in the provision of pharmaceutical formulations. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2015-02-23. The firm is engaged in manufacturing of licensed drugs based on the formulations approved. The firm offers finished pharmaceutical formulations, such as injectables (small volume parenteral, dry powders), tissue bio-adhesive, tablets, capsules, liquid orals (syrup & suspension) and dry syrups (powder). The firm also provides ready-to-fill pellets and multiple unit pellets system (MUPS). Its pellets are categorized as gastrointestinal drug pellets, cardiovascular drug pellets, respiratory drug pellets, anti-obesity drug pellets, anti-depressant drug pellets, central nervous system drug pellets, urological drug pellets, anti-microbial, anti-infective and adjuvant drugs pellets, taste mask drug pellets/powder, nutrition and food supplement drug pellets, anti-cholesterol drug pellets. The firm also provides Iso Amyl 2-Cyano Acrylate, which is a bio-adhesive product.